Activation and sensitization of meningeal nociceptors by PACAP-38: implications for migraine headache - Report - MDSpire

Activation and sensitization of meningeal nociceptors by PACAP-38: implications for migraine headache

  • By

  • Rune Häckert Christensen

  • Andrew Strassman

  • Messoud Ashina

  • Håkan Ashina

  • Rami Burstein

  • August 6, 2025

  • 0 min

Share

Activation and Sensitization of Meningeal Pain Receptors by PACAP-38 in Migraine

Overview

Systemic infusion of PACAP-38 activates meningeal nociceptors in rats, implicating peripheral mechanisms in migraine headache induction. Activation occurs in both C- and Aδ-fibres, with dose-dependent effects observed.

Background

Migraine is a disabling headache disorder involving activation of the trigeminovascular system, particularly meningeal nociceptors. PACAP-38, a neuropeptide found in the dura mater, has been implicated in migraine pathophysiology, as systemic infusion induces migraine attacks in susceptible individuals. Understanding how PACAP-38 activates meningeal nociceptors may clarify migraine mechanisms and guide targeted therapies.

Data Highlights

Dose of PACAP-38 (µg/ml/kg)Neurons TestedNeurons ActivatedActivation Rate (%)
19333
10 (human-equivalent)301550
10044100
Vehicle (saline)Not specified00

Key Findings

  • At the human-equivalent dose (10 µg/ml/kg), PACAP-38 activated 50% of meningeal nociceptors tested, significantly more than vehicle.
  • Activation occurred in both C-fibres (41%) and Aδ-fibres (61.5%) with no significant difference between fibre types.
  • Lower dose (1 µg/ml/kg) activated 33% of neurons, while the highest dose (100 µg/ml/kg) activated all neurons tested.
  • Vehicle infusion did not activate any meningeal nociceptors, confirming specificity of PACAP-38 effects.
  • Findings support peripheral activation of meningeal nociceptors as a mechanism for PACAP-38 induced headache rather than central nervous system effects.

Clinical Implications

These results suggest that targeting PACAP-38 or its receptors on peripheral meningeal nociceptors may be an effective strategy for migraine treatment. Peripheral blockade of PACAP could reduce migraine frequency without requiring central nervous system penetration, potentially minimizing side effects.

Conclusion

PACAP-38 induces headache by activating and sensitizing peripheral meningeal nociceptors, providing a mechanistic basis for its role in migraine pathophysiology and supporting peripheral therapeutic targeting.

References

  1. Original Article 2024 -- Activation and Sensitization of Meningeal Pain Receptors by PACAP-38: Consequences for Migraine Headaches

Original Source(s)

Related Content